Evgen Pharma (LON:EVG) announced its earnings results on Tuesday. The company reported GBX (1.43) (($0.02)) EPS for the quarter, Digital Look Earnings reports.
Shares of EVG stock remained flat at $GBX 7.75 ($0.10) during trading on Tuesday. 78,033 shares of the company were exchanged, compared to its average volume of 207,445. Evgen Pharma has a 52-week low of GBX 5.50 ($0.07) and a 52-week high of GBX 33 ($0.43). The company has a fifty day simple moving average of GBX 10.19 and a 200-day simple moving average of GBX 15.34. The firm has a market cap of $9.97 million and a P/E ratio of -2.87.
Separately, FinnCap reiterated a “corporate” rating on shares of Evgen Pharma in a research note on Tuesday.
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer.
Featured Story: Cost of Equity
Receive News & Ratings for Evgen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evgen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.